國邦醫藥(605507.SH):公司股東擬協議轉讓股份引入戰略投資者
格隆匯8月20日丨國邦醫藥(605507.SH)公佈,基於公司戰略發展需要,引入看好公司價值和看好公司未來發展的戰略投資者,共同推動醫藥產業的創新發展,公司持股5%以上股東濰坊仕琦匯股權投資合夥企業(有限合夥)(以下簡稱“仕琦匯”、“轉讓方1”)、濰坊洪德輝股權投資合夥企業(有限合夥)(以下簡稱“洪德輝”、“轉讓方2”)及紹興世慶德企業管理諮詢合夥企業(有限合夥)(以下簡稱“世慶德”、“轉讓方3”)於2025年8月20日與浙江省國有資本運營有限公司(以下簡稱“國有運營公司”、“受讓方”)簽署了《股份轉讓協議》(以下簡稱“本協議”),仕琦匯、洪德輝及世慶德擬通過協議轉讓的方式向國有運營公司轉讓其首次公開發行股票前持有的公司股份38,306,303股,佔公司總股本的比例爲6.85%。本次權益變動後,仕琦匯、洪德輝及世慶德合計持有公司股份27,411,021股,佔公司總股本4.91%;國有運營公司持有公司股份38,306,303股,佔公司總股本的比例爲6.85%。
本次股權轉讓完成後,國有運營公司擬支持公司在醫藥領域的全面發展,在產業鏈協同、新業務培育、資本運作等領域積極開展戰略合作,協同公司進一步做大做強。在符合國有運營公司投資標準和要求的前提下,國有運營公司重點支持公司主營業務相關領域的投入,雙方擬在未來的合作過程中加強人員交流,在投資項目研判、新技術論證、場景應用、智庫諮詢等方面開展協同賦能。具體合作內容和進度將根據雙方後續工作進一步落實和推進,尚需雙方根據實際情況共同協商確定後另行簽署合作協議,存在不確定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.